Sorry, you need to enable JavaScript to visit this website.

Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen

TitleRapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen
Publication TypeArticolo su Rivista peer-reviewed
Year of Publication2025
AuthorsMiele, Chiara, Ramadan Dania, Lupacchini Leonardo, Marusic Carla, D’Argenio Valeria, Valente Maria Giovanna, Spila Antonella, Gessoni Gianluca, Alfano Veronica, Ferroni Patrizia, Donini Marcello, and Guadagni Fiorella
JournalInternational Journal of Molecular Sciences
Volume26
Type of ArticleArticle
ISSN16616596
Abstract

The ongoing demand for reliable, cost-effective, and scalable diagnostic solutions during the COVID-19 pandemic emphasized the need for innovative production platforms. In this study, we present a plant-based molecular farming (PMF) strategy for the production of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein fused with an Fc region (RBDw-Fc). The RBDw-Fc antigen was transiently expressed in the Nicotiana benthamiana plant, achieving high yields and purity. Its functionality was assessed through antigen–antibody binding assays. The purified antigen was subsequently employed in the development of a rapid diagnostic blot assay capable of screening plasma EDTA samples from pre- and post-vaccinated as well as pre- and post-infected individuals, demonstrating high sensitivity and specificity. Our results show that the RBDw-Fc-based assay is effective for SARS-CoV-2 detection and offers considerable advantages in terms of production speed, scalability, and cost efficiency compared to traditional systems, such as cell-culture-based production. The assay delivers accurate results in just a few minutes, making it particularly suitable for clinical and resource-limited settings. This study highlights the versatility of PMF as a platform for producing high-quality reagents, with promising applications beyond SARS-CoV-2 diagnostics. The RBDw-Fc antigen-based method provides a model for the rapid, economical, and flexible development of screening tools for emerging infectious diseases and future pandemics. © 2025 by the authors.

Notes

Cited by: 0

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-105006660179&doi=10.3390%2fijms26104500&partnerID=40&md5=6ef6df9e673efc4ae60d637b57a2e30f
DOI10.3390/ijms26104500
Citation KeyMiele2025
PubMed ID40429644